Monday · Nov 16, 2026 · Health Digest · regulation
FDA approves Roche's breast cancer pill giredestrant for ESR1-mutated disease
Patients must have an ESR1 mutation detected by an FDA-authorized test, and the agency authorized FoundationOne Liquid CDx as the companion diagnostic, the FDA said. Roche described giredestrant as a next-generation oral SERD, a drug that blocks and degrades the estrogen receptor.
The approval was also reported by the Seattle Times.
Why it matters: The approval gives patients whose cancer carries this mutation a new oral treatment option after hormone therapy, under the FDA's indication.
References
- FDA approves giredestrant in combination with everolimus for ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancerFDA · fda.gov · 2026-11-16
- FDA approves Roche's Wilserdly (giredestrant) for ER-positive, ESR1-mutated advanced breast cancerRoche · roche.com · 2026-11-16
- Roche's breast cancer pill Wilserdly wins U.S. regulatory approvalThe Seattle Times · seattletimes.com · 2026-11-16